ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US.Viruses · 2026Article
- Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Pregnancy and Hepatitis C Virus.Gastroenterology & hepatology · 2023Article
- Universal screening for hepatitis C - in for a penny, in for a pound.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Review
- Association of Individual and Community Factors With Hepatitis C Infections Among Pregnant People and Newborns.JAMA health forum · 2021Article
- The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- Screening for Hepatitis C Virus: How Universal Is Universal?Clinical therapeutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.